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The objective of the present cross-sectional epidemiological study from Tromsø, North Norway was to 
evaluate the relation between blood pressure and serum parathyroid hormone (PTH). 10419 subjects 
were invited to participate in the fifth Tromsø study and 8128 attended. 7954 subjects had serum PTH 
measured, and among these, information on blood pressure medication was available in 5841 subjects 
(2554 males) with serum calcium within the reference range 2.20-2.60 mmol/L. In a multiple linear 
regression model with age, BMI, serum calcium, serum creatinine, and smoking status as covariables, 
serum PTH was a significant and positive predictor of systolic and diastolic blood pressure in both gen-
ders. When dividing the cohort in PTH quartiles, and adjusting for age, BMI, serum calcium, and serum 
creatinine, the differences between the lowest and highest PTH quartile in systolic and diastolic blood 
pressure were 5.0 and 3.5 mmHg for males and 4.1 and 2.5 mmHg for females, respectively. In previ-
ous studies we have found serum PTH to be a positive predictor for future increase in blood pressure, 
and also that the association between serum PTH and blood pressure cannot alone be ascribed to a 
blood pressure induced increase in urinary calcium excretion. To further elucidate the relation between 
serum PTH and blood pressure, randomized clinical trials with calcium and/or vitamin D supplementa-






Parathyroid hormone (PTH) is a peptide hormone 
secreted from the parathyroid glands. The secretion of 
PTH is mainly regulated by the extra-cellular ionized 
calcium level through a negative feed-back mecha-
nism. Thus, a high ionized calcium level reduces the 
PTH secretion, and conversely, a fall in ionized calci-
um increases the PTH secretion. PTH in turn increases 
the serum calcium level by increasing bone resorption 
and the renal tubular calcium absorption. In addition, 
PTH stimulates the hydroxylation of 25(OH)vitamin D 
to its active metabolite 1.25(OH)2 vitamin D, which in 
turn leads to increased calcium absorption from the in-
testines (1). 
 PTH binds to specific receptors that not only exist 
on the surface of its major target organs bone and kid-
ney cells, but also on the cell membrane of a number 
of other organs such as the nervous system and the 
heart (2). In this way, excessive PTH secretion can 
have a multitude of effects, and PTH has been impli-
cated in disease states like neuropathy and left ventri-
cular hypertrophy (2). 
 There are both epidemiological and experimental 
data linking calcium metabolism to the regulation of 
blood pressure. Thus, a low calcium intake is associa-
ted with an increase in blood pressure (3,4), whereas 
calcium supplementation appears to have a blood pres-
sure lowering effect (5). Similarly, supplementation 
with vitamin D, both to elderly women (6) as well as 
middle-aged men (7), has been reported to significant-
ly reduce the blood pressure. 
 In subjects with a calcium deficit, there is a com-
pensatory increase in the secretion of PTH. One would 
therefore expect a positive association between serum 
PTH and blood pressure, which has been reported 
from most (8-11), but not all studies (12). 
 There are also indications for a causal relation 
between PTH and blood pressure. Thus, subjects with 
primary hyperparathyroidism, where the high serum 
PTH level is caused by a parathyroid adenoma, have 
increased blood pressure (13), and chronic infusion of 
PTH has been reported to cause hypertension (14). 
 Thus, if there is a causal relation between PTH and 
blood pressure, one would expect those with elevated 
serum PTH to increase their blood pressure more over 
time than those with normal PTH levels. In particular, 
one would expect those who increased their PTH 
levels to have the highest increase in blood pressure at 
a later examination, which was demonstrated by us in 
a recent study (15). 
 The Tromsø study, which is a health survey focu-
sing on cardiovascular diseases, was performed for the 
first time in 1974 (16), and has since then been repea-
ted with 6-8 years interval. In the fifth Tromsø study in 
2001 serum PTH was measured in 7954 subjects, 
among whom 1784 also had serum PTH measured in 
the fourth Tromsø study in 1994/1995. Accordingly, a 
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large database was available for a cross-sectional as 
well as a longitudinal study of the relation between 
serum PTH and blood pressure. We here report the 
cross-sectional results for the first time, and also sum-
marize the results of the longitudinal study which has 
been published in more detail previously (15). 
 
 
MATERIALS AND METHODS 
 
In the fourth Tromsø study 1994-1995 all men and wo-
men aged > 24 years who were living in the municipa-
lity of Tromsø, which is the major city in North Nor-
way, were invited to participate. A subgroup was invi-
ted to a second phase that included blood samples for 
hormone analysis. In 2001 all men and women older 
than 29 years, living in the same area, and that partici-
pated in the second phase of the fourth Tromsø study 
or became 30, 40, 45, 60 or 75 years old during 2001, 
were invited to participate in the fifth Tromsø study. 
 On both occasions a questionnaire including use of 
blood pressure medication and smoking status was 
filled in. Smokers were classified as current smokers 
or current non-smokers. Height, weight, and blood 
pressure were measured as previously described (17). 
Body mass index (BMI) was calculated as weight (kg) 
divided by squared height (m). Blood samples were 
drawn in the non-fasting state and analysed for serum 
calcium and creatinine within two months, and for 
serum PTH within 12 months. All samples were stored 
frozen at –70 °C. The analytic methods were as repor-
ted before (17). In our laboratory the reference range 
for serum calcium is 2.20-2.60 mmol/L, for serum 
PTH 1.1-6.8 pmol/L for those < 51 years and 1.1-7.5 
pmol/L for those > 50 years, and serum creatinine 55-
100 mmol/L for women and 70-120 mmol/L for men. 
 
Statistics  
In the statistical analyses only subjects with serum 
calcium in the range 2.20-2.60 mmol/L and not using 
anti-hypertensive medication, were included. Normal 
distribution was evaluated with visual inspection of 
histograms and determination of skewness and kurto-
sis, and all variables used as dependent variables were 
considered normally distributed. 
 A multiple linear regression model was used to ass-
ess gender, age, BMI, smoking status, serum calcium, 
serum creatinine, and serum PTH as independent pre-
dictors of systolic and diastolic blood pressure. There 
was a significant effect of gender, and males and fe-
males were evaluated separately. Linear trends across 
PTH quartiles were tested with linear regression with 
use of covariates as above. A general linear model was 
used to calculate adjusted means for systolic and 
diastolic blood pressure in the PTH quartiles. 
 Unless otherwise stated, all data are expressed as 
mean ± SD. All tests were done two-sided, and P < 
0.05 was considered statistically significant. Statistical 
analyzes were performed with SPSS version 11.0 
(SPSS Inc, Chicago, IL., USA). 
RESULTS 
 
10419 subjects were invited to participate in the fifth 
Tromsø study and 8128 attended. 7954 subjects had 
serum PTH measured. Among these, 7794 subjects 
answered the question on blood pressure medications 
and 6239 were present non-users. 352 subjects had 
serum calcium < 2.20 mmol/L and 46 subjects had 
serum calcium > 2.60 mmol/L, leaving 5841 subjects 
(2554 males) for the present study. The demographics 
of these 5841 subjects are given in Table 1. 
 
Table 1.  Characteristics of the study population. 
 
 Males Females 
N 2554 3287 
Age (years) 57.3 ± 14.5 57.2 ± 14.3 
BMI (kg/m2) 26.6 ± 3.6 26.1 ± 4.4 
Systolic blood pressure (mmHg) 137.3 ± 19.0 134.1 ± 22.3 
Diastolic blood pressure (mmHg) 80.5 ± 11.3 77.5 ± 12.1 
Serum PTH (pmol/L) 3.3 ± 1.5 3.3 ± 1.5 
Serum calcium (mmol/L) 2.36 ± 0.07 2.36 ± 0.08 
Serum creatinine (mmol/L) 96.2 ± 11.9 81.9 ± 9.6 
Current smokers (%) 30.8 30.0 
 
 When the cohort was divided in PTH quartiles, 
there was in both genders a gradual increase in age, 
BMI, and serum creatinine with increasing PTH 
quartile, and a gradual decrease in serum calcium with 
increasing PTH quartile (Table 2). Similarly, there was 
in both genders a gradual and significant increase in 
systolic and diastolic blood pressure with increasing 
PTH quartile. The difference between the lowest and 
highest PTH quartile in age, BMI, serum creatinine, 
and serum calcium adjusted systolic and diastolic 
blood pressure, were for males 5.0 and 3.5 mmHg, res-
pectively, and for females 4.1 and 2.5 mmHg, respec-
tively (Table 3). 
 In the multiple linear regression model, serum PTH 
was a positive and significant predictor of systolic and 





In the present study we have found a significant and 
positive association between serum PTH and both 
systolic and diastolic blood pressure in both genders. 
In addition, there was an increase in age and BMI with 
increasing PTH quartile. Both age and BMI are posi-
tively associated with blood pressure, but the associa-
tion between serum PTH and blood pressure was still 
highly significant after correction for these variables 
and also when serum calcium and creatinine were in-
cluded in the regression model. 
 The relation between blood pressure and PTH has 
been studied by several other authors, and in most 
studies the results are in accordance with ours (8-11). 
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Table 2.  Age, BMI, serum calcium and serum creatinine in relation to serum PTH quartile and gender. 
 










Males PTH quartile 1 (0-2.2 pmol/L) 623 53.6 ± 14.9 26.3 ± 3.4 2.38 ± 0.07 95.0 ± 9.9 
 PTH quartile 2 (2.3-3.0 pmol/L) 640 56.2 ± 14.7 26.4 ± 3.4 2.36 ± 0.07   95.2 ± 10.9 
 PTH quartile 3 (3.1-4.0 pmol/L) 664 58.5 ± 14.1 26.6 ± 3.7 2.35 ± 0.07   96.2 ± 11.0 
 PTH quartile 4 (> 4.0 pmol/L) 
 
627 60.7 ± 13.5 27.0 ± 3.7 2.34 ± 0.08   98.5 ± 14.8 
Females PTH quartile 1 (0-2.2 pmol/L) 857 53.5 ± 15.0 25.5 ± 4.0 2.38 ± 0.08 80.7 ± 8.9 
 PTH quartile 2 (2.3-3.0 pmol/L) 836 56.5 ± 13.5 25.9 ± 4.3 2.36 ± 0.08 81.3 ± 9.1 
 PTH quartile 3 (3.1-4.0 pmol/L) 780 59.3 ± 13.9 26.2 ± 4.4 2.36 ± 0.08 82.4 ± 9.7 




Table 3.  Unadjusted and adjusted systolic and diastolic blood pressure in relation to serum PTH quartile and gender. 
 















Males PTH quartile 1 (0-2.2 pmol/L) 623 133.3 ± 18.2 134.6 ± 17.7 78.5 ± 11.1 78.8 ± 11.0 
 PTH quartile 2 (2.3-3.0 pmol/L) 640 135.5 ± 17.3 135.9 ± 17.2 79.5 ± 10.5 79.7 ± 10.6 
 PTH quartile 3 (3.1-4.0 pmol/L) 664 139.2 ± 19.6 138.5 ± 17.1 81.1 ± 11.2 80.8 ± 10.5 
 PTH quartile 4 (> 4.0 pmol/L) 
 
627  141.0 ± 19.82 139.6 ± 17.7  82.7 ± 11.92 82.3 ± 11.0 
Females PTH quartile 1 (0-2.2 pmol/L) 857 129.8 ± 20.5 132.5 ± 18.4 75.9 ± 11.8 76.4 ± 11.3 
 PTH quartile 2 (2.3-3.0 pmol/L) 836 132.9 ± 22.0 133.4 ± 18.4 77.1 ± 11.7 77.2 ± 11.3 
 PTH quartile 3 (3.1-4.0 pmol/L) 780 135.4 ± 22.1 133.7 ± 18.8 77.8 ± 11.7 77.3 ± 11.6 
 PTH quartile 4 (> 4.0 pmol/L) 814  138.8 ± 23.72 136.7 ± 18.8  79.5 ± 12.72 79.0 ± 11.6 
1Adjusted for age, BMI, serum calcium, and serum creatinine 




Table 4.  Standardized b and t values in the multiple linear regression model in the 2554 males and 3287 females. 
 
 Dependent variable systolic blood pressure Dependent variable diastolic blood pressure 
 Males Females Males Females 
 ß t ß t ß t ß t 
Age (years)   0.39 20.47   0.51 33.38   0.23 11.84   0.22 12.43 
BMI (kg/m2)   0.10   5.28   0.11   7.42   0.20 10.14   0.15   8.84 
Serum PTH (pmol/L)   0.09   4.72   0.05   3.36   0.11   5.43   0.08   4.50 
Serum calcium (mmol/L)   0.11   5.64   0.11   7.05   0.12   6.00   0.15   8.60 
Serum creatinine (mmol/L) –0.01 –0.49 –0.02 –1.28 –0.04 –2.07   0.00   0.12 
Smoking status1    0.05   2.55   0.01   0.96   0.02   0.98 –0.02 –1.23 
1Smokers = 1, non-smokers = 2 




Thus, in the study by John et al. (10) that included 583 
subjects, and in the study by Landin-Wilhelmsen et al. 
(11) that included 347 subject, a positive association 
between serum PTH and blood pressure was found. 
However, in a study by Zachariah et al. (12) no signi-
ficant association between serum PTH and blood 
pressure was found, but that study only included 27 
hypertensive subjects and focused primarily on diasto-
lic blood pressure. We therefore find it fair to conclude 
that the positive association between serum PTH and 
blood pressure now is firmly established. 
 If this relation is causal, one would expect subjects 
with a high serum PTH level to have a higher increase 
in their blood pressure over time than subjects with 
lower serum PTH levels, and also that subjects with an 
increase in serum PTH would experience a correspon-
ding increase in blood pressure. We have recently add-
ressed that issue in an analysis of 1784 subjects with 
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serum PTH measurements in both the fourth Tromsø 
study in 1994/1995 and in the fifth Tromsø study in 
2001 (15). In that study the serum PTH level in the 
males in the fourth Tromsø study was a positive and 
significant predictor of the delta systolic blood pres-
sure (blood pressure in 2001 minus blood pressure in 
1994/1995). Thus, the difference in delta systolic 
blood pressure between those in the highest and those 
in the lowest PTH quartile from 1994/1995 was 3.5 
mmHg. Furthermore, in males the delta serum PTH 
(serum PTH from 2001 minus serum PTH from 
1994/1995) was a significant predictor of delta systolic 
blood pressure. In the females the same trend was 
found, but did not reach statistical significance (15). 
 These findings add to the growing number of indi-
cations that PTH is associated with the development of 
hypertension. However, statistical associations are no 
proof of a causal relation, and could simply reflect co-
variation with factors not measured so far. Further-
more, if there is a causal relation, hypertension could 
induce a PTH increase just as well as an elevated PTH 
level could increase the blood pressure. Regarding the 
latter possibility, intravenous infusion of PTH over a 
two hour period caused an increase in blood pressure 
in healthy male subjects (18), as did a 12-day chronic 
PTH infusion in another group of normal subjects (14). 
However, when the ionized calcium level was kept 
constant during the PTH infusion with a clamping 
technique, Jespersen et al. (19) found a moderate blood 
pressure lowering effect of intravenously infused PTH. 
 Conversely, the blood pressure could have an ef-
fect on the PTH level through its effect on the urinary 
excretion of calcium. Thus, more than 50% of the 
renal calcium reabsorption is passively linked to the 
absorption of sodium in the proximal tubule. Hyper-
tension is associated with a high salt intake, which 
would lead not only to a high sodium excretion, but 
also to a high calcium excretion and consequently 
secondary hyperparathyroidism. 
 This appealing theory has been frequently cited 
(11,20), but has so far not been substantiated. In a re-
cent study we tested this hypothesis by evaluating the 
association between serum PTH and blood pressure in 
relation to excretion of creatinine, sodium, and calci-
um in a morning urine sample in 3620 subjects atten-
ding the fifth Tromsø study (21). We found an increa-
sing urinary calcium/creatinine ratio with increasing 
blood pressure, but this ratio had no effect on the 
positive association between serum PTH and blood 
pressure in a multiple regression model. Furthermore, 
in a subanalysis on a large group of subjects having an 
almost identical urinary calcium excretion, there was 
still a highly significant and positive association be-
tween serum PTH and blood pressure. Accordingly, 
this association cannot alone be explained by a blood 
pressure induced increase in urinary calcium excretion. 
 A high serum PTH is only a marker of calcium de-
ficit, and other variables like intakes of calcium and/or 
vitamin D, as well as levels of serum ionised calcium 
and serum 25-(OH)vitamin D may be the causative 
one(s) regarding blood pressure, and not PTH. Further-
more, the intake of calcium as well as vitamin D is in 
parallel with other nutrients, and it is well known that 
the high degree of intercorrelation among dietary fac-
tors makes it difficult to identify the importance of 
single factors (22). 
 However, there are several mechanisms by which 
PTH might affect the blood pressure. Thus, PTH acti-
vates the renal 1-alpha-hydroxylase resulting in increa-
sed 1.25-(OH)2vitamin D levels which again increases 
the calcium influx into vascular smooth muscle cells, 
causing an increase in vascular tone and blood pres-
sure (23). Furthermore, PTH has been reported to have 
a prosclerotic effect on vascular smooth muscle cells 
(24), which may contribute to vessel wall thickening 
and arteriosclerosis. 
 In conclusion, there are strong indications for a 
causal relationship between an increased PTH level 
and elevated blood pressure. To prove this relation-
ship, one would have to move from epidemiology to 
intervention studies and demonstrate a reduction in 
blood pressure after normalization of PTH in a group 
of subjects with elevated PTH levels. However, this 
has so far not been conclusively demonstrated in a 
large group of subjects, and the clinical implication of 
the blood pressure and parathyroid hormone associa-
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